Found 17 matching trials
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma N/A This study is conducted to evaluate the efficacy, prognosis, adverse effect...
Show More Location
The Second Affiliated Hospital of Fujian Medical University
Learn More & Join Trial
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma NA This study intends to evaluate the efficacy and safety of drug-eluting tran...
Show More Location
Chinese PLA General hospital
Learn More & Join Trial
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA PHASE2 Among resectable biliary tract cancers (BTC) patients, surgery has historic...
Show More Location
Peing University Cancer Hospital
Learn More & Join Trial
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation PHASE2 For patients with recurrent liver cancer after liver transplantation, the m...
Show More Location
Department of Liver Transplantation, the Third Affiliated Hospital of Sun Yat-sen University
Learn More & Join Trial
HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC N/A The purpose of this study is to evaluate the safety and efficacy of hepatic...
Show More Status
Active Not Recruiting
Location
The first hospital of China medical university
Learn More & Join Trial
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma PHASE2 To observe and evaluate the efficacy and safety of selective internal radio...
Show More Location
Multiple Locations
Learn More & Join Trial
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma NA This is a prospective, single-arm, phase II clinical study designed to eval...
Show More Location
Multiple Locations
Learn More & Join Trial
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial PHASE2 Atezolizumab and bevacizumab was approve for advanced unresectable hepatoce...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma N/A Systemic therapy is the primary option for managing advanced hepatocellular...
Show More Learn More & Join Trial
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001) N/A This is a retrospective, multicenter, real-world cohort study designed to e...
Show More Status
Active Not Recruiting
Location
Zhongda Hospital, Southeast University
Learn More & Join Trial